Understanding how KAT6A affects a type of acute myeloid leukemia
Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemia
This study is looking at a protein called KAT6A that might be stopping blood cells from developing properly in acute myeloid leukemia (AML), and by using special techniques, the researchers hope to find ways to help these leukemia cells grow into healthy blood cells, which could lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10897963 on NIH RePORTER |
What this research studies
This research investigates the role of KAT6A, a protein that may block the maturation of blood cells in acute myeloid leukemia (AML). The team uses advanced techniques like CRISPR to identify how inhibiting KAT6A can promote the differentiation of leukemia cells, potentially leading to better treatment options. By focusing on MLL-rearranged AML, the study aims to find new ways to reactivate the normal development of blood cells and reduce cancer cell proliferation. Patients may benefit from insights that could lead to more effective therapies for this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with MLL-rearranged acute myeloid leukemia.
Not a fit: Patients with other types of leukemia or those who do not have MLL-rearranged AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help patients with acute myeloid leukemia achieve better outcomes.
How similar studies have performed: Previous research has shown promise in targeting epigenetic factors in leukemia, suggesting that this approach could yield significant advancements.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Blanco, Mario Andres — University of Pennsylvania
- Study coordinator: Blanco, Mario Andres
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.